BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34819726)

  • 1. E7-Targeted Nanotherapeutics for Key HPV Afflicted Cervical Lesions by Employing CRISPR/Cas9 and Poly (Beta-Amino Ester).
    Xiong J; Tan S; Yu L; Shen H; Qu S; Zhang C; Ren C; Zhu D; Wang H
    Int J Nanomedicine; 2021; 16():7609-7622. PubMed ID: 34819726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperbranched poly(β-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer.
    Gao X; Jin Z; Tan X; Zhang C; Zou C; Zhang W; Ding J; Das BC; Severinov K; Hitzeroth II; Debata PR; He D; Ma X; Tian X; Gao Q; Wu J; Tian R; Cui Z; Fan W; Huang Z; Cao C; Bao Y; Tan S; Hu Z
    J Control Release; 2020 May; 321():654-668. PubMed ID: 32114092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy.
    Zhu D; Shen H; Tan S; Hu Z; Wang L; Yu L; Tian X; Ding W; Ren C; Gao C; Cheng J; Deng M; Liu R; Hu J; Xi L; Wu P; Zhang Z; Ma D; Wang H
    Mol Ther; 2018 Oct; 26(10):2443-2455. PubMed ID: 30241742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of CRISPR/Cas9 system in cervical carcinogenesis.
    Gao C; Wu P; Yu L; Liu L; Liu H; Tan X; Wang L; Huang X; Wang H
    Cancer Gene Ther; 2022 May; 29(5):466-474. PubMed ID: 34349239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
    Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
    Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
    Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
    Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
    Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
    Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells.
    Hu Z; Yu L; Zhu D; Ding W; Wang X; Zhang C; Wang L; Jiang X; Shen H; He D; Li K; Xi L; Ma D; Wang H
    Biomed Res Int; 2014; 2014():612823. PubMed ID: 25136604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
    Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
    Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Dependence on Continued Expression of the Human Papillomavirus 16 E7 Oncogene in Cervical Cancers and Precancerous Lesions Arising in Fanconi Anemia Pathway-Deficient Mice.
    Park S; Park JW; Pitot HC; Lambert PF
    mBio; 2016 May; 7(3):. PubMed ID: 27190216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.
    Hu Z; Ding W; Zhu D; Yu L; Jiang X; Wang X; Zhang C; Wang L; Ji T; Liu D; He D; Xia X; Zhu T; Wei J; Wu P; Wang C; Xi L; Gao Q; Chen G; Liu R; Li K; Li S; Wang S; Zhou J; Ma D; Wang H
    J Clin Invest; 2015 Jan; 125(1):425-36. PubMed ID: 25500889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.
    Kennedy EM; Kornepati AV; Goldstein M; Bogerd HP; Poling BC; Whisnant AW; Kastan MB; Cullen BR
    J Virol; 2014 Oct; 88(20):11965-72. PubMed ID: 25100830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
    Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
    Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.
    Zhen S; Hua L; Takahashi Y; Narita S; Liu YH; Li Y
    Biochem Biophys Res Commun; 2014 Aug; 450(4):1422-6. PubMed ID: 25044113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
    Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
    Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
    Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
    Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice.
    Jubair L; Lam AK; Fallaha S; McMillan NAJ
    PLoS One; 2021; 16(1):e0223288. PubMed ID: 33411765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy.
    Chen J; Zhao S; Tan W; Wang T; Wu S; Wang C; Jiang Y; Zhou T; Zhang Z; Zhao L
    Sci Rep; 2021 Oct; 11(1):20083. PubMed ID: 34635698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene.
    Jabbar SF; Abrams L; Glick A; Lambert PF
    Cancer Res; 2009 May; 69(10):4407-14. PubMed ID: 19435895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo.
    Hu D; Zhou J; Wang F; Shi H; Li Y; Li B
    Arch Gynecol Obstet; 2015 Dec; 292(6):1345-54. PubMed ID: 26093522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.